Dose-Response Relationship, Immunologic
"Dose-Response Relationship, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
| Descriptor ID |
D004306
|
| MeSH Number(s) |
G12.300
|
| Concept/Terms |
Dose-Response Relationship, Immunologic- Dose-Response Relationship, Immunologic
- Dose Response Relationship, Immunologic
- Immunologic Dose-Response Relationship
- Dose-Response Relationships, Immunologic
- Immunologic Dose Response Relationship
- Immunologic Dose-Response Relationships
- Relationships, Immunologic Dose-Response
- Relationship, Immunologic Dose-Response
- Relationship, Immunologic Dose Response
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Immunologic".
This graph shows the total number of publications written about "Dose-Response Relationship, Immunologic" by people in this website by year, and whether "Dose-Response Relationship, Immunologic" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 11 | 11 |
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 7 | 7 |
| 1999 | 0 | 11 | 11 |
| 2000 | 0 | 14 | 14 |
| 2001 | 0 | 10 | 10 |
| 2002 | 0 | 9 | 9 |
| 2003 | 0 | 8 | 8 |
| 2004 | 0 | 18 | 18 |
| 2005 | 0 | 7 | 7 |
| 2006 | 0 | 7 | 7 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2012 | 1 | 4 | 5 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 3 | 3 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 3 | 3 |
| 2021 | 1 | 7 | 8 |
Below are the most recent publications written about "Dose-Response Relationship, Immunologic" by people in Profiles.
-
Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology. 2022 03; 75(3):531-540.
-
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021 11 11; 184(23):5699-5714.e11.
-
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Rep Med. 2021 09 21; 2(9):100405.
-
Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. Pediatr Rheumatol Online J. 2021 Aug 30; 19(1):137.
-
Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. J Crohns Colitis. 2021 Jun 22; 15(6):950-959.
-
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. J Crohns Colitis. 2021 Jun 22; 15(6):938-949.
-
High Dose IFN-β Activates GAF to Enhance Expression of ISGF3 Target Genes in MLE12 Epithelial Cells. Front Immunol. 2021; 12:651254.
-
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021 02 11; 137(6):751-762.
-
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respir Med. 2021 04; 9(4):373-386.
-
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. J Crohns Colitis. 2020 Sep 16; 14(9):1202-1213.